Identifying treatment response to antihypertensives in patients with obesity-related hypertension

• Main Authors: Ilse M. Schrover, Jannick A. N. Dorresteijn, Jodine E. Smits, A. H. Jan Danser, Frank L. J. Visseren, Wilko Spiering
• Format: Article
• Language: English
• Published: BMC 2017-10-01
• Series: Clinical Hypertension
• Subjects: Hypertension; Obesity; Treatment; Interaction
• Online Access: http://link.springer.com/article/10.1186/s40885-017-0077-x

Abstract Background In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. Methods Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. Results Systolic BP response to aliskiren was higher in patients with a BMI > 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (−21 mmHg versus -4 mmHg). In patients with a hsCRP > 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (−15 mmHg versus −7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was −13 mmHg when heart rate > 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. Conclusion In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. Trial registration NCT01138423 . Registered June 4th, 2010.